Navigation Links
Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
Date:5/17/2012

BALTIMORE, May 16, 2012 /PRNewswire/ -- In an effort to voice concern on biosimilars pathways for patients with primary immunodeficiency diseases (PIDD), the Immune Deficiency Foundation (IDF) offered oral testimony at last week's U.S. Food and Drug Administration (FDA) public hearing on draft guidance of biosimilars products. IDF urged the FDA to exempt immunoglobulin (Ig) therapies from the biosimilars pathways in order to protect the safety of patients with PIDD.

PIDD occurs in people born with an immune system that is either absent or hindered in its ability to function, causing an array of illnesses. Many of these patients require Ig therapy, a biologic medicine, for long-term management. Ig therapies are derived from human blood product, or plasma, and can differ in terms of processing and end composition.

"The FDA should restrict Ig therapies from the biosimilars pathways until the science advances significantly," said Marcia Boyle, president and founder, IDF. "Patients with primary immunodeficiency diseases depend on frequent antibody replacements with Ig therapy in order to fight infections."

The FDA recognizes each Ig brand as unique with no generic equivalent— Ig products are not clinically interchangeable. Current science cannot demonstrate that two products will provide the exact same clinical results for a large number of patients or that switching patients from one product to another will pose no additional risks.

Boyle's testimony urged the FDA to follow the example set by the European Medicines Agency and exempt Ig therapy from the biosimilars pathway, or to at the least require that biosimilars products undergo clinical trials to determine whether a proposed interchangeable therapy will offer patients the same clinical outcome. Additionally, Boyle requested that the FDA prohibit automatic substitution of a biosimilars with an original biologic.

"We believe the FDA's foremost responsibility
'/>"/>

SOURCE Immune Deficiency Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. EUPROBIO 2008 Presentation to Highlight Latest Immune Research
4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
5. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
6. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. Peptimmune Presentations at Upcoming Events
9. Protein-printing technique gives snapshots of immune system defense
10. Visualizing asthma-causing immune cells at work
11. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Milpitas, CA (PRWEB) March 02, 2015 ... chain events annual report which summarizes and ... generated by its EventWatch™ 24X7 global event ... practitioners can subscribe to a free trial period of ... of supply chain incidents that can negatively impact revenue, ...
(Date:3/2/2015)... GAITHERSBURG, Md. , March 2, 2015 /PRNewswire/ ... Gaithersburg -based biotechnology company focusing on the ... and next generation antibody agents based upon a ... received a 2015 Life Sciences Impact Grant Award ... (MCDED).  The grant, created by MCDED, is awarded ...
(Date:3/2/2015)... March 2, 2015  Pfenex Inc. (NYSE MKT: ... development of biosimilar therapeutics, today announced that it ... Healthcare Conference in Miami, FL at the Loews Miami Beach ... officer of Pfenex, will provide an overview of ... 12th at 9:00 am ET. A live audio webcast and ...
(Date:3/2/2015)... , March 2, 2015 Editor ... bottom.   Moments ago, Analysts Review released ... Sunshine Heart (NASDAQ: SSH ), Synergetics ... Medical (NASDAQ: ELOS ), Spectranetics (NASDAQ: ... Review provides a single unified platform for investors, to hear ...
Breaking Biology Technology:Resilinc Publishes 2014 EventWatch™ Supply Chain Disruption Annual Report 2Resilinc Publishes 2014 EventWatch™ Supply Chain Disruption Annual Report 3VLP Therapeutics Wins the 2015 Life Sciences Impact Grant Award from the Montgomery County Department of Economic Development 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4
... Oct. 10 DermTech International, Inc.,a biotechnology ... early,detection of melanoma and other diseases, today ... Advisory Board. Dr. Quackenbush is a,Professor of ... Institute and Professor of Computational Biology and ...
... For Hispanic-Americans without health,insurance, it can be difficult ... prescription medicines. However, help is available for people,who ... doctors. Listen to this report from Pfizer ... Registered journalists can access video, audio, text, graphics ...
... MISSISSAUGA, ON, Oct. 9 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ... the,third quarter of 2007. All dollar amounts referenced herein ... 31, 2007, our cash and cash equivalents and restricted ... 31, 2007. With,the repayment of our convertible notes during ...
Cached Biology Technology:DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Company's Scientific Advisory Board 2Vasogen Announces Third Quarter 2007 Results 2Vasogen Announces Third Quarter 2007 Results 3Vasogen Announces Third Quarter 2007 Results 4Vasogen Announces Third Quarter 2007 Results 5Vasogen Announces Third Quarter 2007 Results 6Vasogen Announces Third Quarter 2007 Results 7Vasogen Announces Third Quarter 2007 Results 8Vasogen Announces Third Quarter 2007 Results 9Vasogen Announces Third Quarter 2007 Results 10Vasogen Announces Third Quarter 2007 Results 11Vasogen Announces Third Quarter 2007 Results 12Vasogen Announces Third Quarter 2007 Results 13
(Date:3/2/2015)... , March 2, 2015 Synaptics Inc. ... of human interface solutions, today announced a new ... designed to enable rapid and secure transactions and ... for gaming is a turnkey solution providing mouse ... to quickly integrate fingerprint ID solutions into their ...
(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
(Date:3/2/2015)...   Neurotechnology , a provider of high-precision biometric, ... Software Development Kit (SDK). The SentiGaze algorithm enables ... webcams to track eye movements and generate heatmaps based ... can be used for applications such as analysis of ... SDK can also be used to develop interfaces for ...
Breaking Biology News(10 mins):Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Personal Data Protection Company Launches New Product 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... Tri-Band WLAN Module in SDIO Card Form Factor, ... today,announced the SX-SDWAG, the first world,s first wireless ... form factor. Designed for,wireless local area network (WLAN) ... ideal for battery-operated portable devices in,the medical, weights ...
... consolidating world databases of ocean organisms have demoted ... culled from 34 regional and highly specialized inventories. ... ( www.marinespecies.org ) contains about 122,500 validated marine ... some 56,400 aliases 32% of all names ...
... Calif.) Michael Gazzaniga, professor of psychology at UC ... the Study of the Mind, has received the Humboldt ... "Professor Gazzaniga is a true pioneer in reaching ... the relationship between mind and brain," said UCSB Chancellor ...
Cached Biology News:Silex Introduces SX-SDWAG 802.11a/b/g SDIO Radio Card for OEM Portable Device Applications 2Census of Marine Life lists 122,500 known species, over halfway to complete inventory by Oct. 2010 2Census of Marine Life lists 122,500 known species, over halfway to complete inventory by Oct. 2010 3Census of Marine Life lists 122,500 known species, over halfway to complete inventory by Oct. 2010 4Census of Marine Life lists 122,500 known species, over halfway to complete inventory by Oct. 2010 5Neuroscientist Michael Gazzaniga awarded Humboldt Prize 2
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
... Killer Cell Receptor-P1, clone 1C10 ... Hybridoma produced by the ... mice immunized (BALB/c X C57BL/6)F1 ... and mouse myeloma cellline. ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Biology Products: